Anavex Life Sciences Corp (AVXL)

[RedShoulder]

$50 Billion total market size for Opioids and NSAIDs pain relievers.

Anavex should get a decent size cut of that market if the human trials follow the murine mouse trials; like falconer said, the pain relief system on murine mice and veterinarians studies always coincides with human studies. Veterinarians give the same pain relievers to animals that humans use. AVXL has never failed a trial, and the drugs have always been proven to be safe.

Global in 2018 and is projected to expand at a CAGR of 1.8% during the forecast period. Increasing prevalence of diseases that cause chronic pain, such as cancer, postsurgical pain, lower back pain, fibromyalgia, and arthritis, is driving the market.

This is on top of the multi-Billion NSAID market for pain relievers. "NSAIDs Market to Reach USD 24.35 Billion"

This is why we are a top % gainer today, once this news gets around we will move towards the $25 target recently posted.

The trials will be short, FDA will be quick.

Opioids market valued at USD 25.4 billion:

https://www.grandviewresearch.com/industry-analysis/opioids-market#:~:text=The%20global%20opioids%20market%20size,arthritis%2C%20is%20driving%20the%20market.

NSAIDs Market to Reach USD 24.35 Billion by 2027:

https://www.globenewswire.com/news-release/2020/05/28/2040374/0/en/NSAIDs-Market-to-Reach-USD-24-35-Billion-by-2027-Surging-Research-on-Selective-Cyclooxygenase-2-Inhibitors-to-Boost-Growth-Fortune-Business-Insights.html